Category: ACN Newswire

Highlights (Unaudited relevant data for the six months ended 28 February 2025)- Revenue increased by 7.5% YoY to approximately RMB1,247.5 million;- Number of student enrolled up by 4.4%, against last corresponding period, to approximately 100,300;- Cash and cash equivalents amounted to RMB2,070.8 million, ample liquidity;- Interim dividend 6.6 HK cents per share, dividend payout ratio 30%.HONG KONG, Apr 25, 2025 - (ACN Newswire via SeaPRwire.com) – Edvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) has announced its unaudited FY2025 Interim Results for the six months ended 28 February 2025 (the “Reporting Period”). With the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) giving it advantage in school operation, the Group continued to increase investment in artificial intelligence (AI), industry-education integration, internationalization, innovation and entrepreneurship, teaching team, and campus facilities, as such, strengthened its high-quality education brand.During the Reporting Period, the Group made revenue of approximately RMB1,247.5 million, a 7.5% increase against the last corresponding period. The increase was mainly attributable to the increase in student enrollment at the Group’s Huashang Vocational College and Urban Vocational College, as well as the rise in the average tuition fees at its schools in China. The Group’s cash and cash equivalents amounted to RMB2,070.8 million, indicating of its ample liquidity. The number of students enrolled in the Group’s schools continued to climb year by year, reaching approximately 100,300, up by approximately 4.4% year-on-year. The Board of Directors recommended payment of an interim dividend of HK6.6 cents per share for the six months ended 28 February 2025, representing a dividend payout ratio of 30%, which is also marked as the Group’s 12th consecutive dividend payout since listing.From left to right: Ms. Liu Wenqi, Chief Operating Officer; Ms. Liu Yi Man, Executive Director and Chief Executive Officer; Mr. Liu Yuk Tung, Chief Financial Officer.Increasing investment in high-quality education to build a world-renowned education brandThe Group has held fast to the educational philosophy of “building a century-old prestigious school and nurturing outstanding talents for China”, believing that strategic investment and visionary planning are crucial to developing a high-quality education brand. During the Reporting Period, the Group acquired the land use rights of three plots on the Jiangmen campus, giving it a solid foundation to continue to expand school capacity and accommodate future student growth. The Group also actively brought in industry experts and academic leaders and vigorously expanded its dual-qualified teaching team. Moreover, via overseas inclusive courses, expanding its international institutional cooperation network, and broadening teachers’ and students’ international horizon the Group has been facilitating overseas expansion of China’s vocational education.Closely following national policies and actively embracing educational reforms and vigorously developing “AI + talent training” and industry-education integrationIn the new era of AI deeply empowering education, the Group has adopted "AI + talent cultivation" as core strategy, comprehensively upgrading the education system by building intelligent education platform, introducing AI teaching assistants, AI general education courses, etc. The Group is also continuously strengthening the integration of industry and education, focusing on emerging fields such as AI, smart manufacturing, and the digital economy. Through collaborations with leading enterprises including Huawei, Baidu, and JD.com, the Group has established industry-specific colleges, workshops, and real-world corporate projects to ensure precise alignment with industry needs, as well as continuing to nurture highly-skilled talent for national strategic industries.Future ProspectsLooking ahead, open to opportunities of the industrial upgrade of the GBA and development of national strategic emerging industries, the Group will closely follow national policies and seize the “Golden 15-year window” for high-quality development in higher vocational education. It will actively align with talent demands of the GBA, flexibly optimize its academic program offerings, and continue to enhance education quality and strengthen its educational distinctiveness, striving to build a globally renowned education brand, while delivering long-term sustainable value to shareholders.About Edvantage Group Holdings LimitedEdvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) is the largest private business higher education and vocational education group in the Greater Bay Area, and an early mover in education sector in pursuing international expansion, listed in Hong Kong Main Board on 16 July 2019. The total number of full-time student enrolments of the Group was approximately 100,300 as of 28 February 2025. Operated 9 private education institutions, namely, Guangzhou Huashang College (Applied Undergraduate), Guangzhou Huashang Vocational College (Higher Vocational Education) and Guangdong Huashang Technical School (Secondary Vocational Education) located in Guangdong Province, the PRC; Urban Vocational College of Sichuan (Higher Vocational Education) and Urban Technician College of Sichuan (Secondary Vocational Education) in Sichuan Province, the PRC; GBA Business School (GBABS) in Hong Kong, the PRC; Global Business College of Australia (GBCA) and Edvantage Institute Australia (EIA) in Australia; as well as Edvantage Institute (Singapore) (EIS) in the downtown of Singapore.While focusing on school operations, the Group also actively fulfil corporate social responsibility, extensively contributing to social welfare programmes including charity, poverty alleviation, education and revitalisation, in order to take the initiative in repaying society through action. Since its listing, the Group has made outstanding contributions in the field of ESG and has won the “Best ESG Innovation Award” from Zhitong Finance and the “Outstanding Enterprise for ESG Innovative Practice” from Gelonghui in 2024. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 25, 2025 - (ACN Newswire via SeaPRwire.com) – TIME Interconnect Technology Limited (“TIME Interconnect”, Stock Code: 1729.HK, with its subsidiaries collectively referred to as the “Group”) , a leading manufacturer of cable assembly, digital cable, and server products, has recently announced its final results for the year ended 31 December 2024 is pleased to announce its final results for the year ended 31 December 2024 (the “Current Year” or “FY2024”). The Group achieved record-breaking growth, driven by strategic expansions in high-margin sectors and excellent execution. During the FY2024, global economic growth experienced a notable slowdown, primarily due to persistently high borrowing costs, the gradual withdrawal of fiscal support, and heightened geo-economic fragmentation. These factors collectively exerted downward pressure on overall market demand. Moreover, cyclical imbalances among major economies began to stabilise, with economic activities gradually returning to potential levels. Amid this challenging macroeconomic landscape, the Group demonstrated agility and resilience by accelerating its business transformation and product upgrades. Notably, it capitalised on the surging demand for server and data centre infrastructure driven by the rapid emergence of artificial intelligence (AI), which remained a key growth engine and contributed to strong revenue performance in the data centre and specialty cable segments. For the Current Year, the Group recorded revenue amounting to HK$7,388.8 million, represented an increase of HK$2562.5 million or 53.1% as compared with HK$4,826.3 million for the Previous Year. Operating profit for the Current Year was HK$623.6 million, represented an increase of HK$190.2 million or 43.9%, as compared with HK$433.4 million for the Previous Year. The operating profit margin dropped slightly from 9.0% to 8.4% for the Current Year, primarily attributable to an increase in research and development expenditure. Net profit of the Current Year was HK$450.5 million, represented an increase of HK$172.9 million or 62.3%, as compared with HK$277.6 million for the Previous Year, with the net profit margin raised from 5.8% to 6.1% for the Current Year*. Basic earnings per share for the Current Year was HK23.2 cents as compared to the basic earnings per share of HK14.2 cents in the Previous Year. Business Review The Group’s turnover by market sector is as follows: Market SectorTurnover (HK$ million) Share of Turnover Year ended 31 December 2024Nine months ended 31 December 2023ChangesYear ended 31 December 2024Nine months ended 31 December 2023Cable assembly Data centre1,213.5 791.0 53.4% 16.4% 16.4% Telecommunication566.8 555.4 2.1% 7.7% 11.5% Medical equipment 816.6 258.0 216.5% 11.1% 5.3% Industrial equipment 29.2 24.4 19.7% 0.4% 0.5% Automotive 157.7 100.4 57.1% 2.1% 2.1% Digital cable Networking cable 1,179.9 788.7 49.6% 16.0% 16.4% Specialty cable 237.0 77.0 207.8% 3.2% 1.6% Server 3,188.1 2,231.4 42.9% 43.1% 46.2% Total 7,388.8 4,826.3 53.1% 100% 100% Data centre sectorThe revenue of the data centre segment increased by HK$422.5 million to HK$1,213.5 million for the Current Year as compared to HK$791.0 million for the Previous Year. Benefiting from the surge in artificial intelligence and server upgrades, shipment levels remained strong during the FY2024, and the sector remained to be the highest revenue contributor in the cable assembly business. Telecommunication sectorRevenue from the telecommunication sector rose by HK$11.4 million to HK$566.8 million for the Current Year, compared to HK$555.4 million in the Previous Year. Although part of the production capacity has been shifted to data centre sector due to its order volume increased. But better margin orders of telecommunication sector have been retained to improve the product portfolio of overall cable assembly business. Medical equipment sectorDuring the Current Year, the Group paid more attention and efforts in the medical equipment cables business and continued to enhance its medical equipment customers base, as well as to strengthen its R&D capabilities. Benefited from the setup of two new plants last year, Time Kunshan and Time Jiangxi, and expanded production capacity and R&D capabilities for medical equipment cables products, the revenue of the medical equipment sector for the Current Year significantly increased to HK$816.6 million, representing a substantial rise of HK$558.6 million compared to HK$258.0 million for the Previous Year. The Group continued to increase investment in this sector, enhancing both production capacity and R&D capabilities. The Group expects that, with growing health awareness, demand for medical equipment will continue to rise. Industrial equipment sectorDespite the underperforming global economic recovery, and the pressures from high inflation and interest rates on economic activities, the revenue of the industrial equipment sector increased. The revenue rose from HK$24.4 million in the Previous Year to HK$29.2 million for the FY2024, representing an increase of 19.7%. Automotive sectorDespite the ongoing impact of geopolitics and the trade war, sales orders for automotive wire harness products remained at a relatively low level. However, the revenue of the automotive sector increased to HK$157.7 million for the Current Year, up by HK$57.3 million from HK$100.4 million in the Previous Year. The Group still believes that the automotive wiring products can help the Group to provide its customers with a broader product portfolio, and to step into a new business sector by enriching the Group’s business portfolio and broadening its unique customer base, which can capture opportunities brought by the booming electric vehicle market. Additionally, the Group established a wholly-owned subsidiary, Linkz Cables Mexico S. de R.L. de C.V. ("Linkz Mexico"), in Mexico, aiming to increase its market share outside China and Asia. Networking cable sectorEven a lot of negative factors, such as the divergences between countries, war, high interest rates, strong US dollar and high inflation, were remained exist, during the FY2024, overseas orders for the networking cable sector continued to improve, with revenue rising to HK$1,179.9 million, an increase of HK$391.2 million from HK$788.7 million in the Previous Year. The increase in copper prices reflects ongoing growth in market demand. Furthermore, the establishment of Linkz Mexico has helped enhance the Group's market share in the United States and Mexico. Specialty cable sectorDriven by the surge in demand for high-speed cables fuelled by artificial intelligence applications, the specialty cable sector experienced robust growth. Revenue for the sector increased significantly to HK$237.0 million for the FY2024, up by HK$160.0 million or 207.8% compared to HK$77.0 million in the Previous Year. The growth in high-speed cables also contributed to improved profit margins, further enhancing the Group's overall profitability. Server sectorDuring the Current Year, the revenue of the server sector grew significantly to HK$3,188.1 million, an increase of HK$956.7 million compared to HK$2,231.4 million in the Previous Year. Despite challenges in the first half of the year due to shortages in key component supplies, the Group worked very hard to find all the business solutions to cope with this situation. Finally, the supply of these key components has been resolved and the production has been resumed immediately, leading to a strong recovery in the second half. Continued strong demand for servers further drove business growth. ProspectDespite challenges in the macroeconomic environment, including global growth uncertainties and geopolitical tensions, the Group’s management remains confident in its future business development. Looking ahead, the Group will continue to embrace flexibility and continuous innovation, focusing on strengthening supply chain resilience, expanding international presence, and driving diversified business growth to ensure long-term development. In the FY2024, the Group has proactively expanded its overseas business with the establishment of Linkz Mexico, a wholly-owned subsidiary. The new factory is expected to commence full production within the year, primarily manufacturing digital cables and automotive wire harness products. This aligns with the "China-Plus-One" strategy, mitigating geopolitical risks and ensuring export stability. With the rapid growth in demand for electric vehicles, automotive wire harness products have become a key driver for the Group’s next phase of growth. Meanwhile, the acceleration of global 5G deployment, along with the normalisation of remote work and cloud applications, will continue to propel the Group’s growth in telecommunications cables and server solutions. In the server segment, the Group has successfully expanded its data centre product line through its JDM/ODM business model, continuously customising solutions to meet the needs of brand clients. Riding on the PRC government’s “channelling computing resources from the eastern areas to the western regions” initiative and leveraging Luxshare Group’s technological platform and market resources, the Group will further scale its data centre business and seize the significant market opportunities arising from the rapid advancement of artificial intelligence, big data, and cloud computing. In the medical technology sector, Dr. Cua Tin Yin Simon, the Group’s CEO, remains optimistic about the prospects， “In 2024, the Group further increased its investments, including a stake in a Japanese medical and healthcare company with a proven operational history of over 30 years. In addition, the Group invested in a UK-based startup with seven years of professional experience in haptics and virtual reality. This company has developed innovative wearable haptic technology capable of simulating weight, resistance, and assistive forces in virtual environments. With initial applications in digital health and fitness within the spatial computing space, the technology merges wellness, fitness, and gaming to optimise human performance—targeting the vast markets of gaming and neuromuscular rehabilitation. The Group believes that these strategic investments will allow it to leverage the companies’ technological expertise and create synergy in developing medical-related products, particularly in R&D, manufacturing, and global market expansion. In line with our expansion strategy, two new liaison offices—Time US and Time UK—have also been established to deepen our global business presence.” Additionally, in 2024, Dr. Cua facilitated the establishment of the Medical Engineering and Innovation Council under the Federation of Hong Kong Industries (FHKI), where he serves as Co-Chair alongside Chuang Tzu Hsiung, Chairman of both FHKI and the Hong Kong New Industrialisation Development Alliance. The council is dedicated to establish a medical engineering frontier tracking mechanism to deeply explore technology transformation and commercialization potential. Secondly, it constructs an integrated "Government-Industry-University-Research-Investment" collaborative platform, consolidating government policies, university R&D, clinical resources, and industrial capital. By establishing joint laboratories and rapid conversion channels, it accelerates the commercialization of scientific research outcomes. Simultaneously, the council strengthens cross-border cooperation by connecting global innovation networks, introducing international certification bodies and technology transfer platforms, assisting Hong Kong enterprises in overcoming overseas market access barriers, and establishing cross-border industry-university-research bases to reinforce the region's innovation hub status. Finally, it implements a full-cycle industry cultivation program, providing comprehensive support for start-ups from prototype development, regulatory certification, clinical trials to mass production. While promoting traditional industry transformation and global market expansion, it facilitates the formation of a complete ecosystem for Hong Kong's medical technology industry - "Research & Development - Conversion - Industrialization" - to address global health challenges and enhance international competitiveness. The Group believes that, while pursuing business growth, it is also essential to fulfill its corporate social responsibility by actively addressing social issues such as health, innovation, and industry upgrading. Moving forward, the Group will focus on high-potential areas, leveraging innovation, collaboration, and sustainability to strengthen its core competitiveness and position itself as a leading provider of network solutions and medical technology infrastructure, creating greater value for shareholders and society. Key Milestone - Establishment of the Medical Engineering and Innovation Council About TIME Interconnect Technology Limited TIME Interconnect Technology Limited is a well-established supplier of customised interconnect solutions with over 30 years’ experience in the industry. The Group is headquartered in Hong Kong, and has manufacturing facilities in Shanghai, Suzhou, Jiangxi and Huizhou, the People’s Republic of China (“PRC”), Japan and Mexico. The Group currently manufactures and supplies a wide variety of copper & optical fiber cable assemblies, digital cable products and servers which are produced to the specifications and designs of its individual customer partners. Its products are used by a number of established PRC and international customers in a variety of market sectors, including telecommunication, data centre, industrial equipment, medical equipment, automotive wire harness, digital cable and server. This press release is disseminated by Bright Communications International Limited on behalf of TIME Interconnect Technology Limited. For further enquiries, please contact Bright Communications International Limited: Ms. Ashley KungTel: (852) 46371627Mob: (852) 6608 9927Email:ashley.kung@brightcommns.com*Note: The financial year end date of the Company has been changed from 31 March to 31 December in July 2023. For details, please refer to the Company’s announcement dated 24 July 2023. In view of this change, the consolidated financial statements of the Group cover the twelve-month period from 1 January 2024 to 31 December 2024 and the comparative figures cover the nine-month period from 1 April 2023 to 31 December 2023. It should be noted that the financial data presented herein are being compared with that for the nine-month period ended 31 December 2023. The difference in duration of the two financial periods should be considered when making year-on-year comparisons. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Apr 25, 2025 - (ACN Newswire via SeaPRwire.com) - The Board of Directors (“Board”) of Mooreast Holdings Ltd. (“Mooreast” or the “Company”), and together with its subsidiaries, the “Group”) wishes to provide an update on several recent developments: Completion of Multi-Buoy Mooring Upgrade Project at Gulf of ThailandFurther to the Company’s announcement dated 12 November 2024, Mooreast wishes to update that the project to upgrade a multi-buoy mooring (“MBM”) system off the eastern shore of the Gulf of Thailand was completed recently. The Group expects to recognise approximately S$8.8 million for this project in the first half of the financial year ending 31 December 2025 (“1H2025”).The successful completion underscores the Group’s capabilities to handle sizeable mooring projects within the oil and gas (“O&G”) industry. Orders related to the O&G sector had been building up in 2H2024, and have continued to gain momentum in the first four months of FY2025. Even with the delivery of the MBM project, current orders at hand are at least equal to those at the end of FY2024. Accordingly, the Group expects revenue in 1H2025 to exceed the S$13.7 million recorded in 1H2024. Additionally, the Group does not expect that the administrative and other operating expenses to increase significantly in FY2025 given that the current staffing is sufficient to support operations and business development in the near term and the absence of fees for professional services rendered to support the Group’s business repositioning efforts in FY2024. Management is actively reviewing and implementing cost control measures to improve overall cost efficiency and profitability moving forward.Update on Floating Wind Energy Projects in Europe and North AsiaOn 1 January 2025, Mr. Eirik Ellingsen (“Mr. Ellingsen”), a Norwegian with deep experience in the offshore and marine sector, was appointed Chief Executive Officer (“CEO”). In the last four months, he has been working closely with Mr. Sim Koon Lam (“Mr Sim”), the founder, Executive Director and Deputy Chairman, on business development strategies amid an increase in commercialisation of floating wind energy projects worldwide.Mr. Ellingsen has been actively engaging players involved in floating wind energy projects in Europe and North Asia, and participated in the WindEurope conference in Copenhagen, Denmark, earlier this month. While the ‘first wave’ of implementation – involving largely demonstration and precommercial projects – had been delayed by the supply chain disruptions caused by the COVID-19 pandemic, the industry has clearly advanced to the ‘second wave’ – commercialisation at scale. With the progress toward commercialisation, the Environmental Resources Management’s “Q3 2024 Global Offshore Wind Market Update" reported over 390 GW of floating wind projects in various planning and development stages. Compared to 50-100 megawatts (“MW”) typical at pre-commercialisation, the latter involves projects of at least 500 MW each. Many of these projects are reaching the final investment decision (“FID”) phase in 2026 and 2027. These include multigigawatt (“GW”) scale projects which can contribute substantially to the growth of offshore wind capacity globally. Typically, mooring and rigging solutions, including anchors, chains, and ropes, account for between 5% to 10% of the total value of each floating wind energy project. Approximately 5.5 GW of floating wind capacity is expected to reach FID in the next 24-36 months. Of this, about two-thirds involve projects in Europe, including those in the North Sea, while a third will come from North Asia. These projects may be deemed as the addressable market of Mooreast. As the Group is currently not targeting U.S. floating wind energy projects, it is not subject to U.S. Government tariffs for its products. Already, Mooreast is working closely with these projects and has indicated its component costings. As these progress to full implementation, developers and partners are looking for a reliable manufacturer capable of handling the large volumes of anchors and mooring components required for these large-scale projects. The Group believes it is uniquely positioned, given its status as Asia’s only ultra-high power anchor designer and manufacturer and its global footprint. Mooreast recently opened new offices in Taiwan and Malaysia in June and July 2024, respectively, expanding its presence in the Asian region.The Group continues to assess the ability of its present facility at 51 Shipyard Road in Singapore to handle production of anchors and components as these projects advance to formal tender, noting that developers have indicated suppliers would need to demonstrate beforehand sufficient capacity to handle the indicative volume. Should such orders escalate beyond the current capacity of the existing yard, Mooreast would need to explore access to additional capacity. Meanwhile, the Company continues to develop its supply chain to better serve its customers globally. The Company will provide updates to shareholders as and when there are material developments regarding floating renewable energy projects. BY ORDER OF THE BOARD MOOREAST HOLDINGS LTD.Mr Eirik Ellingsen Chief Executive Officer23 April 2025This announcement has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the EASL Congress 2025, taking place from May 7-10, 2025 in Amsterdam. The presentations include post-hoc analyses of two Phase 2 clinical studies of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, being developed for treatment of metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM). A third presentation will present preclinical results for rimtoregtide (HTD4010), a peptide derived from the Reg3a protein, in liver failure in mice.“Effects of Berberine Ursodeoxycholate (HTD1801) in Patients with At-risk MASH and T2DM”(Presentation SAT-440, Poster Presentation, May 10, 8:30 AM CET)About the Abstract: Due to the ongoing unmet medical need, clinical development in MASH focuses on patients who are at a higher risk of disease progression and outcomes due to the presence of moderate to advanced fibrosis (defined as at-risk MASH). The purpose of this analysis was to assess the effects of HTD1801 in patients with at-risk MASH and T2DM as defined by baseline MRI cT1 >875 ms. Eighteen weeks of treatment with HTD1801 resulted in substantial improvements in key hepatic and cardiometabolic parameters in patients with at-risk MASH and compared to placebo, twice as many patients achieved a reduction in liver fat content (MRI-PDFF) or fibroinflammation (cT1) that have been associated with improvements in liver histology. These data are particularly insightful as HTD1801 continues to be evaluated in an ongoing paired biopsy study of patients with at-risk MASH and pre-diabetes or diabetes.“Effects of Berberine Ursodeoxycholate (HTD1801) in Chinese Patients with T2DM and Presumed MASLD”(Presentation SAT-432, Poster Presentation, May 10, 8:30 AM CET)About the Abstract: T2DM typically coexists with other metabolic abnormalities such as hyperlipidemia, obesity, and MASH that can exacerbate T2DM and can lead to a worse prognosis with increased risk for mortality and cardiovascular outcomes. In a Phase 2 study in patients with T2DM, HTD1801 achieved the primary endpoint with a significant decrease in HbA1c. Based on the latest diagnostic criteria, it is likely that a substantial subgroup of the study may have had concurrent metabolic dysfunction-associated steatotic liver disease (MASLD). The purpose of this analysis was to evaluate the benefits of HTD1801 in patients with T2DM and MASLD identified by baseline controlled attenuation parameter values >288 dB/M (correlated to 5% liver fat content). HTD1801 treatment demonstrated both dose-dependent improvements in cardiometabolic and hepatic parameters in patients with T2DM and MASLD. These data suggest HTD1801 can comprehensively address metabolic and cardiovascular risk factors beyond glycemic control.“A Comparison of the Protective Effects of Rimtoregtide (HTD4010) and DUR-928 on Acute Liver Failure in Mice”(Presentation FRI-141, Poster Presentation, May 9, 8:30 AM CET)About the Abstract: The purpose of this study was 1) to test the potential protective effects of HTD4010 in an LPS-induced model mimicking acute liver failure in mice and 2) compare these effects to DUR-928, which is currently in late-stage development for the treatment of alcohol-associated hepatitis. In an LPS-induced mouse model mimicking acute liver failure, HTD4010 resulted in significant improvement in survival rates (greater than 2-fold) compared to the model control. These protective effects of HTD4010 were significantly greater than DUR-928. These findings provide evidence that HTD4010 may have a beneficial effect on acute liver conditions including alcohol-associated hepatitis and other acute-inflammatory-related conditions.About Berberine UrsodeoxycholateBerberine ursodeoxycholate (HTD1801) is an orally delivered, gut-liver anti-inflammatory metabolic modulator being developed for the treatment of metabolic and digestive diseases. HTD1801, an ionic salt of berberine and ursodeoxycholate, is a new molecular entity with a unique dual mechanism of action: AMP kinase activation and NLRP3 inflammasome inhibition. These two key mechanistic pathways have been associated with improvements in insulin resistance, glucose metabolism, lipid metabolism, and hepatic inflammation, potentially providing a comprehensive treatment platform for the multifaceted nature of complex metabolic diseases. HTD1801 is being developed for multiple indications. HTD1801 met the primary endpoint in two Phase 3 clinical trials in patients with type 2 diabetes mellitus (T2DM), demonstrating a clinically meaningful effect on HbA1c. In both trials, key secondary endpoints were achieved, suggesting multiple advantages of HTD1801 including improvement in cardiometabolic risk indicators. In addition to T2DM, HTD1801 efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH) has been demonstrated in a Phase 2a clinical trial, and a global multicenter Phase 2b trial assessing the histologic benefit of HTD1801 is currently ongoing, with topline results expected in 2025.About RimtoregtideRimtoregtide (HTD4010) is a clinical-stage compound in development for acute inflammatory-related indications including alcoholic hepatitis (AH). It is a peptide derived from the Reg3a protein with immunomodulatory, anti-inflammatory, and anti-apoptotic effects. HTD4010 has been evaluated in animal models of acute pancreatitis and acute liver failure, where protective effects were observed. A completed Phase 1 clinical trial of HTD4010 in healthy subjects demonstrated a favorable safety profile. AH is caused by chronic heavy alcohol abuse or a sudden, drastic increase in alcohol consumption. It is characterized by severe inflammation and, ultimately, liver failure and death. There is currently no approved treatment for AH and only a few drug candidates are in clinical development. The current standard of care focuses on symptom management, including abstinence, treating inflammation and providing nutrition.About HighTide TherapeuticsHighTide Therapeutics, Inc. (Stock Code: 2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional, multi-targeted therapies with poly-indication potential across metabolic diseases with significant unmet medical needs. HighTide is currently developing several clinical assets and associated global intellectual property rights, and advancing multiple mid-to-late-stage clinical trials including therapies for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG) and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), HighTide’s lead drug candidate, received Fast Track designation from the United States Food and Drug Administration for both MASH and PSC and Orphan Drug designation for PSC. HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project in China.For more information, please visit www.hightidetx.comContact: pr@hightidetx.com Copyright 2025 ACN Newswire via SeaPRwire.com.

JAKARTA, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) - South East Asia’s first premium service airline, PT TransNusa Aviation Mandiri, is further strengthening its presence in Singapore by increasing the frequency of its scheduled flights for the Jakarta – Singapore route to two times daily from today.This announcement comes barely a month after TransNusa successfully launch scheduled flights to Perth from its base in Bali.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said that TransNusa has plans to further strengthen its network connectivity this year.In line with this, TransNusa launched its second daily flight to Singapore today. The additional flight, 8B 153, departed at 12.10pm from the Terminal 3 Soekarno – Hatta International Airport and arrived Singapore Changi Airport at 14.40pm today. While its additional flight, 8B 154, departed Changi Airport at 15.30pm and arrived at the Soekarno – Hatta International Airport at 16.20pm.“TransNusa will continue to operate the current scheduled flight, 8B 151, which depart Soekarno – Hatta International Airport at 07.55am and arrive at 10.45am at the Changi Airport,” Datuk Bernard said, adding that the current flight, 8B 152, depart Changi Airport at 11.45am and arrive in Jakarta at 12.30pm.TransNusa has been consistently achieving milestones since the introduction of a new top management led by aviation veteran, Datuk Bernard Francis. The airline, which introduced its first international flight on April 14, 2023, has expanding its wings from South East Asia to the Asia Pacific region within a short span of 2 years.Datuk Bernard attributes the airline’s successes and accelerated growth within the last 24 months to their customised business model and the vastly experienced management team.Datuk Bernard stressed that for its international flights, TransNusa not only provide premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our passengers will enjoy check-in baggage of between 20kgs to 30 kgs, depending on the product purchased,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.“For the highest package, FLEXI-PRO, we provide more complete services such as free baggage 30kgs, free to choose seats, free food, and drinks, priority at check-in and boarding. In addition, TransNusa also provides its FLEXI-PRO passengers with the ability to be able to change their flight schedule without restrictions and obtain refund when needed.”TransNusa, which aims to ensure its passengers travel with ease and comfort, has also configured their A320s with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers.” said Datuk Bernard, adding that the ticket price for the Jakarta – Singapore route starts from as low as SGD52 (USD40).DATUK BERNARD FRANCIS… TransNusa to focus on strengthening network connectivityTransNusa, A Short HistoryTransNusa, which had to close it business operation in September 2020 due to impact of the Covid-19 pandemic on the aviation industry, started operations again after injection of new shareholders and a new management team led by aviation expert, Datuk Bernard, in October 2022.Within 6 months, the airline introduced its first international route between Jakarta and Kuala Lumpur and celebrated its first-year anniversary for this route on April 14, 2024.“When we re-launched TransNusa in October 2022, we started from the bottom again. Everything was new because the pandemic had disrupted the aviation business operations boundaries. As such we re-created and customised our business operations and strategy model of being the first Premium Service Carrier based on the post-pandemic scenario,” Datuk Bernard explained.TransNusa launched its first international route between Jakarta and Kuala Lumpur in April, 2023, followed by the Jakarta – Singapore route on November 20, 2023. After which, the airline successfully launched three more new international routes by the end of 2023. TransNusa’s aggressive international growth strategy combined with its domestic business operations approach has enabled the airline to experience strategic growth in the last two years.Since the takeover of new shareholders and the injection of a new management team, TransNusa has been making headlines in Malaysia, Singapore, China and Australia with news of being the first airline in Indonesia and the world to develop and introduce a new domestic route connecting Bali and Manado. TransNusa also became the second Indonesian airline to receive approval to fly to China.About TransNusaEstablished in 2005, TransNusa started its operation by providing chartered flights. It began its commercial flights in 2011. After ceasing operations due to the Covid-19 pandemic, TransNusa relaunched itself in 2021 as a low-cost airline in its domestic market. In 2023, TransNusa introduced a new business model making it the first Premium Service Airline in the region. The new business model will apply only to its international routes. TransNusa introduced its first international route in April this year. The airline introduced its Jakarta – Kuala Lumpur round trip route and had its maiden flight on April 14. The airline is currently based in Jakarta Soekarno-Hatta International Airport.Passengers can book their flights on the TransNusa website (www.transnusa.co.id), through authorized travel agents in Singapore and Indonesia, or by contacting the airline's customer service centre at, +62216310888. For the Singaporean market, passengers can contact TransNusa’s General Sales Agent, Chariot Travels Pte Ltd, at +65 86602719.Media ContactTrina Thomas Rajtrina@myqaseh.org+60124992672 (watsapp) Copyright 2025 ACN Newswire via SeaPRwire.com.

- Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in the number and suppressive function of Tregs compared to baseline values. - Clinically, patients with Frontotemporal Dementia (FTD) demonstrated minimal to no cognitive decline throughout the study period. Treatment was well tolerated, no serious adverse events were reported, and all 5 patients completed the study.Houston, TX, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) - Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute (Houston, TX) with funding from The Peggy and Gary Edwards Endowment Fund. Study patients received subcutaneously administered CTLA4-Ig, followed by a 5-day course of low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up. The study aims to enroll up to 10 patients, and these interim results include data from the first 5 patients with mild to moderate FTD who have completed the full course of treatment.Dr. Arun Swaminathan, Coya’s Chief Executive Officer followed: “The results thus far are consistent with previously published encouraging data from an open-label investigator-initiated study of patients with ALS treated with low-dose IL-2/CTLA4-Ig. This interim data in FTD provides us further confidence of our approach to target and enhance Treg biology to address devastating neurodegenerative diseases including ALS and FTD”.Previous biomarker data presented by the Company demonstrated that FTD patients exhibit a compromised immunosuppressive function of regulatory T cells (Tregs), along with increased peripheral levels of inflammatory cytokines and chemokines, dysregulation of monocytes, and systemic activation of the inflammatory cascade, supporting the critical role of the immune system in the pathophysiology of FTD.One previous study showed that a cohort of 68 patients with FTD worsened by an average of 3.57 points over a 12-month period per the Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR‐FTLD) scale (Knopman et al. Brain 2008; 131(11): 2957-2968). In addition, patients with FTD typically have shorter survival times and more rapid rates of cognitive and functional decline compared to patients with Alzheimer’s disease (Rascovsky et al. Neurology 2005; 65(3): 397-403).Dr. Fred Grossman, Coya’s Chief Medical Officer stated: “We are excited with the results observed in this initial group of patients with this proof-of-concept study. We believe that the increase in Treg numbers and suppressive function, with subsequent anti-inflammatory biological activity still to be evaluated, underscores the potential for this low-dose IL-2/CTLA4-Ig combination to be further studied as a therapy for FTD, for which there are no currently approved treatments.”Summary of Interim Study Results Overall, treatment with low-dose IL-2 and CTLA4-Ig was well tolerated. All 5 patients enrolled in the first cohort completed the study and received the investigational treatment as planned. The most common adverse events were mild injection site reactions. No serious adverse events were reported.Treg numbers and suppressive function increased after the first treatment cycle (p < 0.01 and p < 0.05, respectively, and remained at higher significant levels throughout the treatment period.Clinical functional assessments were performed in all patients at pre-specified timepoints over the course of the study using validated tools, including the Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR‐FTLD) scale, the Montreal Cognitive Assessment (MoCA) scale, and the Progressive Aphasia Severity Scale (PASS). Results of the functional tests show that, on average, these five FTD patients treated with low-dose IL-2 and CTLA4-Ig combination exhibited minimal to no cognitive decline over the course of the study, compared to pre-treatment values.The Company intends to publish and/or present more comprehensive data in a future peer-reviewed meeting and/or publication.About Frontotemporal DementiaFrontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterized by altered behavior and language, with a progressive decline in executive function.1 FTD affects an estimated 30,000 Americans.2 FTD is categorized clinically into various subtypes; the main three include behavioral-variant frontotemporal dementia and two language variants, semantic dementia (also known as semantic variant primary progressive aphasia) and progressive non-fluent aphasia (also known as non-fluent variant primary progressive aphasia). It's a presenile dementia, meaning it can occur in younger individuals, often between the ages of 45 and 64. The average age of onset is 58, with an average survival time of 7.5 years.1,2References1. Knopman et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008; 131(11): 2957-29682. Rascovsky et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005; 65(3): 397-403About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.COYA 302 is a combination treatment comprised of low-dose IL-2 and CTLA4-Ig is an investigational therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of Tregs and suppress the inflammation produced by activated monocytes and macrophages. Coya is developing COYA 302 for the treatment of fatal neurogenerative diseases characterized by chronic inflammation and Treg dysfunction.For more information about Coya, please visit www.coyatherapeutics.com Forward-Looking StatementsThis press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Investor Contact:David Snyder, CFOdavid@coyatherapeutics.com CORE IRBret Shapirobrets@coreir.com 561-479-8566Media ContactsFor Coya Therapeutics:Kati Waldenburgmedia@coyatherapeutics.com212-655-0924 Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 23, 2025 - (ACN Newswire via SeaPRwire.com) – On 22 April, Earth Day, an electrifying cycling event was held across Guangdong and Macau. Batch Bicycles and Hyatt Place Zhuhai jointly organised Ride Macao, an event to explore the country on wheels and celebrate Earth's Day with green travel.In today’s fast-paced city life, people are often busy with work and various affairs that they gradually leave nature and sports behind. The Ride Macao event was designed to break this shackle and spread the values of living green, protecting the environment and the cycling lifestyle to everyone.Starting from Hyatt Place Zhuhai and arriving at Hengqin Port, the carefully planned route combined the picturesque natural scenery and unique cityscape along the way with the ease of cruising through customs. Riders enjoyed the magnificent view of the sea and sky during the journey while also experiencing the unique charm of the blend of history and modernity found along the streets and lanes of Macau. This was not only a long-distance ride, but also a deep dialogue with the earth to embrace green living.Ride Macau by Batch Bicycles (a brand of Covation)Batch Bicycles Products DisplayBatch Bicycles is a global brand of Covation Holdings Limited (Covation). Covation is a global holding company headquartered in Hong Kong. Covation's vision of consumer-centric innovation is driven by its diverse portfolio of outdoor brands, including Huffy, Niner Bikes, Batch Bicycles, Royce Union, VAAST and Buzz E-Bikes, which are available to consumers in more than 50 countries and territories around the world through an extensive global distribution network. The company ships more than 5 million bicycles annually. Covation holds a wide-ranging licensing portfolio with world-class partners such as Disney, Marvel, Lucasfilm, National Geographic, Ford, Nickelodeon, Hasbro, and Panama Jack. The vast distribution network includes leading global retailers such as Walmart, Amazon, Target, Swire, Big W, Academy, Argos, Smyths, and many other international outlets.The mission of Batch Bicycles is to 'make cycling easier'. With a wide range of products including mountain bikes for conquering mountains, road bikes for riding the pavement, gravel bikes and cycling equipment specially designed for teenagers. Batch Bicycles are designed to provide cycling enthusiasts around the world with a comfortable and smooth cycling experience through innovative designs and high-quality configurations. The Macao Ride is a vivid manifestation of Batch Bicycles brand philosophy to make cycling easier and encourage people to venture out of the concrete city to explore the world and embrace nature through cycling. Copyright 2025 ACN Newswire via SeaPRwire.com.

WATERLOO, ONTARIO, Apr 23, 2025 - (ACN Newswire via SeaPRwire.com) - Axibo Inc., a Waterloo-based robotics innovator celebrated for its groundbreaking 4D volumetric capture technologies and serving customers like Netflix and Apple, today announced a $12 million funding round. This investment includes $11 million from prominent external investors and an additional $1 million from Axibo's founders Anoop Gadhrri, Sohaib Al-Emara, and Reiner Schmidt, whose passion for robotics began back in 2019 with their university's first autonomous vehicle. The funding launches Axibo's ambitious new division dedicated to advanced humanoid robotics.Axibo FoundersWith a track record of thousands of cinema robots delivered internationally, Axibo will now be leveraging Waterloo's exceptional AI, robotics, and precision engineering talent to spearhead advancements in humanoid robotics."We see humanoid robots as the next major milestone in productivity since the Industrial Revolution," said Anoop Gadhrri, co-founder and CEO of Axibo. "Canada is exceptionally well-positioned with its talent and resources. Our commitment is to drive this forward, placing Canada prominently on the global robotics stage."Axibo is actively seeking visionary engineers passionate about developing unprecedented technologies and shaping the global future of humanoid robotics. Early team members will not only create groundbreaking prototypes but directly contribute to substantial societal advancements through robots engineered for safe and intelligent integration into healthcare, logistics, industrial automation, and personal assistance. By fostering an innovation-driven culture emphasizing rapid prototyping and autonomy, Axibo empowers its engineers to experiment freely and iterate swiftly."We envision a future where every household benefits from humanoid robotics," Gadhrri emphasized. "Axibo's technology aims to significantly elevate productivity and everyday life across Canada and beyond."The company's immediate milestones include accelerating proprietary manufacturing processes, expanding its engineering and AI teams, and advancing capabilities in robot autonomy and dexterity. The new division's first robot prototype, temporarily code-named "T.E.B.", will debut in early 2026, demonstrating advanced agility and intelligence.If you're ready to build what's next in robotics, Axibo invites you to join the pioneering team positioning Canada at the global forefront of robotics innovation.To learn more or apply, visit axibo.ai.Contact InformationAnoop GadhrriCEOanoop@axibo.com6476675999SOURCE: Axibo Inc.Related Images Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年4月23日 - (亞太商訊 via SeaPRwire.com) - 4月22日地球日當天，一場別具意義的騎行之旅跨越粵澳！百琦自行車攜手珠海橫琴凱悅酒店，共同舉辦騎行澳門活動，以車輪丈量土地，用綠色出行的方式，為地球母親慶生。在快節奏的都市生活中，人們總是被繁忙的工作與各項事務纏身，逐漸遠離了自然與運動。而此次騎行澳門活動，正是為了打破這種桎梏，將綠色環保的價值主張與騎行的生活方式傳遞給每一個人。從珠海出發，到達橫琴口岸，絲滑通關後，精心規劃的路線串聯起沿途如畫的自然風光與獨特的城市景致。既能在騎行中飽覽海天相接的壯闊，又能穿梭於澳門街巷，感受歷史與現代交融的獨特魅力。這不僅是一場騎行，更是一次與地球的深度對話，一場對綠色生活的躬身實踐。百琦自行車（高飛控股旗下品牌）騎行澳門活動百琦自行車展示據悉，百琦自行車（Batch Bycyles）是高飛控股集團（Covation）旗下全球品牌。高飛控股集團（Covation）是一家總部在香港的全球控股公司。高飛控股集團（Covation）始終推動以消費者為中心的創新願景，旗下擁有豐富多樣的戶外品牌，包括Huffy、Niner Bikes、Batch Bicycles、Royce Union、VAAST 和 Buzz E-Bikes，憑藉廣泛的全球分銷網路，為全球50多個國家和地區的消費者提供騎行產品，每年自行車運送量超500萬輛。不僅如此，高飛控股集團還與迪士尼、漫威、盧卡斯影業、國家地理、福特、尼克國際兒童頻道、孩之寶和巴拿馬傑克等世界級合作夥伴緊密合作，擁有龐大且多元的許可組合，其產品通過沃爾瑪、亞馬遜、塔吉特、太古、Big W、Academy、Argos、Smyths 等全球領先零售商，走進千家萬戶。百琦自行車始終以"讓騎行變得更簡單"為初心。產品線豐富多元，不管是征服山野的山地車，還是在城市中暢行的公路車，亦或是礫石自行車，還有專為青少年打造的騎行裝備，憑藉創新設計與優質配置，為全球騎行愛好者帶來舒適暢快的騎行體驗。此次騎行澳門活動，正是百琦自行車踐行品牌理念的生動體現，鼓勵人們走出鋼筋水泥的圍城，在騎行中探索世界，擁抱自然，讓騎行變得更簡單。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年4月23日 - (亞太商訊 via SeaPRwire.com) - 在發展新質生產力的道路上，科技創新能夠催生新產業、新模式、新動能，起著至關重要的主導作用，是發展新質生產力的核心要素和關鍵變量，也是根本驅動力。融資租賃龍頭海通恆信（1905.HK）緊跟國家以「科技創新引領新質生產力發展」的目標導向，把握新質生產力發展機遇，推動業務創新發展與突破。2024年，海通恆信堅定立足租賃本源，不斷提升核心競爭力，在經營穩健、結構優化、風險管控、融資管理等方面取得了較好成績，經營效能持續提升。年內，海通恆信實現收入總額及其他收入、收益人民幣88.55億元，淨利潤人民幣15.13億元，基本每股收益人民幣0.17元。公司還長期重視股東回報，擬派發2024年年度股息每10股人民幣0.40元（含稅），派息總額達人民幣3.29億元，與股東共享發展成果。堅持創新驅動發展，加快創新產品落地海通恆信的四大經營方針中，「創新驅動」緊隨「跨界思維」之後，與之緊密相連，是公司高質量發展的引擎。公司深入挖掘新產業政策帶來的業務機遇，在國家大規模設備更新戰略政策下，持續提升產融對接能力，進一步創新業務模式，發展特色化融資租賃專業服務，為業務開拓釋放新動能，實現與產業夥伴的共贏。針對戰略新興領域業務，海通恆信深入研究新興產業和未來產業，堅持創新驅動發展，助力加快推動新質生產力發展與現代化產業體系建設。2024年，公司積極配合上海市融資租賃協會編製《中國綠色租賃年度發展報告》，推動出台了上海市綠色租賃業務認定的地方標準；海通恆信「油翠新生」方案榮膺上海市融資租賃行業協會首屆全國綠色融資租賃年度創新案例，低空經濟項目入選江西省租賃保理行業協會2024年度科技金融優秀案例，居家養老設備租賃項目入選2024年度上海融資租賃行業創新案例之「最佳案例」，大規模設備更新專項支持方案「更新租(2024)」入選2024年度上海融資租賃行業創新案例之「優秀案例」。與此同時，海通恆信的小微子公司濕電子化學品行業國產替代租賃項目、智能可循環物流托盤租賃項目共同入選2024年度上海融資租賃行業創新案例之「優秀案例」；恆運子公司榮獲第四屆中國汽車金融與產業發展競爭力論壇暨汽車行業年度「星辰獎」之「2024年汽車金融新質生產力創新產品獎」。創新優化融資模式，為產業化佈局敞開空間產品創新是海通恆信「創新驅動」方針的A面，而融資管理創新則是B面，二者彼此協同、互相呼應，成就了公司創新發展的深刻內涵。2024年，公司不斷創新融資方式，豐富綠色融資品種，有效降低融資成本，助力公司產業化轉型。年內，海通恆信持續深化與銀行等金融機構的合作，優化授信條件，融資管理水平不斷提升。截至2024年12月31日，公司與64家金融機構建立授信合作關係，累計獲得授信額度約為人民幣1,131億元，其中未使用的授信餘額約為人民幣615億元；有息負債中，直接融資餘額佔比49%，間接融資餘額佔比51%。公司直接融資與間接融資比例相對合理、融資結構穩定，融資成本有效降低，2024年計息負債平均付息率為3.37%，較上年下降0.26個百分點。透過創新和豐富融資方式，海通恆信業務產業化佈局發展進一步加快，並獲得了市場廣泛認可。2024年，公司在上海證券交易所成功發行融資租賃行業首單中小微企業支持債券；積極開拓與政府間國際金融組織的合作，成為首家與新開發銀行合作的商業融資租賃公司，獲批的1億美元等值人民幣貸款將用於支持環境保護和能效提升項目。同時，公司還參與編寫了全國首個融資租賃行業債券和資產證券化產品系列指數「中債-融資租賃信用債指數」，助力融資租賃行業資產證券化發展的基礎性建設。此外，基於融資業務在綠色金融領域的創新能力和服務實體經濟的優異表現，公司發行的「海通恆信第十五期綠色資產支持專項計劃」榮獲第八屆不動產證券化與REITs論壇組委會頒發的2024年度「金萃獎」之「最佳綠色ABS產品獎項」、「海通恆信租賃7號資產支持專項計劃」榮獲第九屆CNABS中國資產證券化年度獎「金桂獎」之「最具行業影響產品獎」。受惠於持續優化負債結構、創新融資產品，引導優質資金支持公司鼓勵的產業領域的業務開展，海通恆信連續七年獲得AAA級主體信用評級（展望穩定）。2024年，公司總體債務結構持續改善，資金成本穩步下降，也為其連續穩定派發股息提供了充足的底氣。據統計，自2019年港股上市起，公司連續每年派發2次股息，迄今派息總額超40億元。展望2025年，主動適應新質生產力發展的新要求，合規創新業務模式，推動創新租賃產品的批量化、複製化落地推廣，與企業創新同頻共振，共繪可持續發展新篇章，將是海通恆信的業務重心。通過多元化的創新金融服務解決方案，優化服務新興產業發展的業務模式，海通恆信「融通萬物、助力產業」的願景正逐步照進現實。 Copyright 2025 亞太商訊 via SeaPRwire.com.

KUALA LUMPUR, Apr 23, 2025 - (ACN Newswire via SeaPRwire.com) - EdgePoint Towers Sdn Bhd (“EdgePoint”) – part of EdgePoint Infrastructure, a leading ASEAN-based independent telecommunications infrastructure company, has successfully launched its first solar hybrid site, marking a key milestone in its renewable energy initiatives. This deployment represents a significant step toward advancing sustainable energy solutions in Malaysia’s telecommunications sector.The new solution provides up to 100% of the energy required to operate telecommunications equipment, reducing dependence on diesel fuel. With a 5.9-kilowatt peak (kWp) capacity, the site operates autonomously using photovoltaic (solar) energy, complemented by battery storage.Muniff Kamaruddin, Chief Executive Officer of EdgePoint Towers, said, “We are proud to contribute to the deployment of renewable energy solutions that meet current and future needs for both sustainability and long-term cost efficiency. These solutions are especially important for remote and difficult-to-reach areas, such as transport corridors like highways, tunnels, bridges, or terminals, where quality coverage is essential for transient users. The opportunities to enhance national connectivity are vast, and EdgePoint is eager to continue working closely with our partners to advance sustainable solutions that improve coverage and reduce carbon emissions across the industry. This deployment is expected to reduce the site's annual carbon emissions by approximately 78%, while also ensuring seamless connectivity for travelers along the highway.”Muniff concluded, “Solar energy has proven to be an ideal solution for Malaysia, given its equatorial climate and high levels of solar insolation. By integrating solar power into telecommunications infrastructure, we are reducing reliance on non-renewable energy sources, lowering operational costs, and significantly decreasing emissions. Solar hybrid solutions are an adjacent focus area for us, it is a key part of our broader strategy of implementing innovative, sustainable solutions, driving an industry-wide transformation toward cleaner, more efficient operations and we are optimistic about future collaborations with both Mobile Network Operators (MNOs) and non-MNO clients to help them meet their green objectives. As we expand our renewable energy initiatives, we aim to set new benchmarks for energy-efficient telecom infrastructure in Malaysia, helping our partners transition to greener operations without compromising connectivity, network quality, and reliability.”By the end of 2025, EdgePoint plans to complete more full solar or solar hybrid sites across the country, further strengthening its commitment to sustainable telecom infrastructure.EdgePoint Infrastructure is the fastest-growing multi-country tower company in ASEAN, with 15,800 sites in its portfolio out of which 1,800 sites are in Malaysia making it the second-largest tower company in Malaysia.****ABOUT EDGEPOINT INFRASTRUCTUREEdgePoint Infrastructure is an ASEAN based independent telecommunications infrastructure company that aspires towards Building a Connected, Digital ASEAN. Headquartered in Singapore with operations in Malaysia, Indonesia and the Philippines, through EdgePoint Towers Sdn Bhd, PT Centratama Telekomunikasi Indonesia, Tbk and EdgePoints Towers Inc. respectively, the company is focused on providing sharable and leading-edge telecom structures, small cells and in-building systems. EdgePoint aims to be an industry leader through scale and innovation, driving operational efficiencies through the adoption of analytics and digital technologies. For more information on EdgePoint, please visit https://edgepointinfra.com/. Copyright 2025 ACN Newswire via SeaPRwire.com.

JAKARTA, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - The Indonesia Carbon Capture and Storage Center (ICCSC) is organizing The 3rd International & Indonesia CCS Forum 2025, an international-scale forum aimed at accelerating the development of Carbon Capture and Storage (CCS) technology as a key pillar toward a green economy and sustainable growth in Indonesia. The event will take place on October 7-8, 2025, at Hotel Mulia, Jakarta, featuring over 100 global speakers from various sectors.Belladonna Troxylon Maulianda, Executive Director of ICCSC, emphasized that this forum is designed as a strategic platform to bring together global stakeholders, including governments, industry players, academics, and investors. "CCS plays a crucial role in reducing carbon emissions and supporting Indonesia's net-zero targets. Through this forum, we aim to strengthen global collaboration to address challenges and leverage opportunities in CCS development," said Belladonna.The forum's theme, "Advancing Indonesia as a CCS Hub Leader in the Asia Pacific: Achieving Net Zero and Economic Growth", reflects a shared commitment to driving sustainable growth through clean energy. "We hope this event will generate innovative solutions and policy recommendations to accelerate CCS development in Indonesia and globally," she continued.Evan Lukas, Chairman of the Organizing Committee for The 3rd IICCS Forum 2025, explained that this event will feature various exciting programs, including high-level panel discussions, exhibitions of the latest technology, and strategic networking sessions. "This forum is not only a platform for sharing knowledge but also a place for the birth of strategic partnerships and innovative solutions to global challenges in CCS development," said Evan."We invite all stakeholders, including the government, industry players, and the community, to actively participate in this forum. Together, we can build a network of regional CCS hub towards a low-carbon future and support energy transition" added Evan.ICCSC hopes this forum can become a catalyst for strengthening Indonesia's position as a global leader for regional CCS hub that decarbonize heavy industries, while continuing to meet energy demand and grow economies.Elen Setiadi, Deputy Minister for Energy and Mineral Resources, Coordinating Ministry for Economic Affairs of The Republic of Indonesia expressed appreciation for the forum's organization. "The government fully supports this event as part of efforts to achieve energy transition and net-zero emission targets. CCS is one of the key solutions in Indonesia's clean energy transition," said Elen.The 3rd International & Indonesia CCS Forum 2025 also offers participants the opportunity to interact directly with industry leaders, experts, and policymakers. In addition to the main programs, the event will showcase the latest CCS technology exhibitions featuring innovations from global companies.The ICCSC invites all stakeholders, including strategic partners, industry associations, government representatives, and media, to join this forum. The event is not only a moment for discussion but also for taking concrete steps toward realizing a sustainable clean energy future.For more information on The 3rd International & Indonesia CCS Forum 2025, visit the official website: www.iiccsforum.com About IICCSThe International & Indonesia Carbon Capture and Storage Center (IICCS) is a platform dedicated to promoting CCS technology and facilitating collaboration between governments and industries in addressing climate change through CCS implementation. About ICCSCThe Indonesia Carbon Capture and Storage Center (ICCSC) is a community of experts from various industry, including engineering, science, policy, and business, united by a shared commitment to finding practical solutions to CO2 emission challenges. Through research, innovation, and advocacy, we strive to accelerate carbon capture and storage development in Indonesia and position the country as a Regional CCS Hub. Visit iccscenter.com.Media Contact:info@iccscenter.com+62 878 8721 3208 Copyright 2025 ACN Newswire via SeaPRwire.com.

WELLINGTON, FL, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) - The 2025 U.S. Open Polo Championship®, played at the USPA National Polo Center (NPC) in Palm Beach County, showcased top-tier polo action from March 26 to April 20 and ended this Sunday with a thrilling Final win by La Dolfina Tamera over La Dolfina Catamount in a score of 12-8 in front of a record crowd.Agustina FondaLa Dolfina Tamera wins the U.S. Open Polo Championship® trophy.Watch the U.S. Open Polo Championship on ESPNHosted by legendary ESPN broadcaster Chris Fowler, the U.S. Open Polo Championship Final was played on the U.S. Polo Assn. Stadium Field, in front of an electric crowd. The game will be broadcast to a large global audience across multiple ESPN platforms, including ESPN2 on Saturday, April 26, at 10:30 AM EDT, as well as Primetime on ESPNews on Sunday, April 27. Check your local listing for air times.U.S. Polo Assn. Supports the Sport and Equine CharitiesAs the sport's most prestigious tournament in North America, the U.S. Open Polo Championship features some of the world's best polo players and equine athletes. Once again, the tournament was supported by U.S. Polo Assn., the official brand of the United States Polo Association (USPA), with U.S. Polo Assn. branded jerseys for teams, NPC staff uniforms, umpire outfitting, player prizes, and monetary donations to several local charities. Throughout the season, the global, sport-inspired brand has donated some $25,000 to polo charities and equine welfare, among others, including Homes for Horses Coalition, Museum of Polo and Hall of Fame, Polo for Life, Polo Players Support Group, Polo Pony Rescue, Polo Training Foundation, Replay Polo, Retired Racehorse Project, Vinceremos Therapeutic Riding Center, and Work to Ride Program."U.S. Polo Assn. is proud to once again support the U.S. Open Polo Championship, broadcast on ESPN platforms as one of the top sporting events of the Spring season alongside the Masters and Kentucky Derby," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the multi-billion-dollar U.S. Polo Assn. brand. "It's an honor to have legendary ESPN broadcaster Chris Fowler as the host this year, alongside Kenny Rice and Adam Snow, bringing more access and awareness to the sport of polo as we continue to reach more and more sports fans and consumers around the world."An Electric Game Watched Live by a Record-Breaking CrowdThousands of fans at NPC witnessed the action-packed final game of the Gauntlet of Polo® tournament series, which included the C.V. Whitney Cup®, the USPA Gold Cup®, and the U.S. Open Polo Championship. In a year that delivered record-breaking crowds week in and week out, the thrilling final was filled with great plays from the world's best players on both teams, La Dolfina Tamera featuring 10-goal player Adolfo Cambiaso; Diego Cavanagh; Matt Coppola; and Alejandro Poma, and La Dolfina Catamount featuring 10-goal player Poroto Cambiaso; Jesse Bray; Rufino Merlos and Scott Devon. For the second year in a row, the U.S. Open Polo Championship Final presented an epic showdown between two of the world's top polo players who are also father and son.Adolfo, age 50, who has been defeated in the last two U.S. Open Finals, the last one being to his son, Poroto, age 19, reclaimed victory in this game to take home his 10th U.S. Open title. It was just this week that Adolfo turned 50, thus reclaiming the championship trophy as his perfect birthday present. Adolfo is considered the best polo player in history, having also won more than 17 titles in the Argentine Open Polo Championship, and is considered the "Greatest of All Time (GOAT)" beside other sports icons such as Tiger Woods, Michael Jordan, and Tom Brady.Adolfo Cambiaso, Age 50, Defeats Son Poroto Cambiaso, Age 19, Wins Back TrophyLa Dolfina Catamount came out strong at the beginning of chukker 1, but La Dolfina Tamera soon took the momentum and kept the game close. The score was tied at 6-6 after the 3rd chukker. After some clutch goals by Poma in chukkers 3,4, and 5 and an impressive long goal from Adolfo, Tamera continued to have the lead. Though Poroto scored an incredible 5 goals overall, and Bray scored in the 6th and final chukker, both of Catamount, to bring it to 11-8, there just wasn't enough time for a comeback. Tamera clinched their win with a thrilling goal by Coppola to make the final score 12-8. La Dolfina Tamera's Poma won MVP, scoring a team-high 4 goals, with Adolfo scoring 3 goals."Congratulations to La Dolfina Tamera on a remarkable victory in the U.S. Open Polo Championship," said Stewart Armstrong, Chairman of the USPA. "I would also like to thank and acknowledge all participating teams throughout the 2025 Season at NPC for leaving it all on the field for the sport.""Thank you to all of our patrons, players, sponsors, and sports fans for their passion and support for the sport of polo and the USPA this season," Armstrong added.The USPA National Polo Center, the Winter Equestrian Capital of the WorldGuests at NPC, the world's premier polo facility based in Palm Beach County, watched the action-packed match from many luxurious settings, including the sidelines, stadium boxes, tailgate tents, the grandstands, as well as from the U.S. Polo Assn. MVP Lounge, home to the iconic Sunday Polo Brunch. Sports fans also had exclusive on-site shopping opportunities at the flagship USPA Shop location, where limited-edition sport-luxury pieces in The Polo Club Collection and the U.S. Polo Assn. Global Collection were available for fans wanting to take home a piece of the sport of polo. New this year included a 4ocean branded custom-designed bracelet, an element of the longstanding partnership between the two brands, with 4Ocean being the Official Recycling Partner of the 2025 U.S. Open Polo Championship.Photo Credits: Agustina FondaLa Dolfina Tamera wins the U.S. Open Polo Championship® trophy.La Dolfina Tamera's Adolfo Cambiaso hooks the mallet of his son Poroto Cambiaso of La Dofina Catamount in a defensive play to ultimately win the U.S. Open Polo Championship® in a score of 12-8.The record-breaking crowd at the USPA National Polo Center (NPC) watching the heart-pounding U.S. Open Polo Championship® Final.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. Historic deals with ESPN in the United States and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, NBA, and MLB, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global and digital growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the USPA and manages the global, multi-billion-dollar U.S. Polo Assn. brand. Through its subsidiary, Global Polo Entertainment (GPE), USPA Global also manages Global Polo TV, which provides sports and lifestyle content. For more sports content, visit globalpolo.com.Contact InformationShannon StilsonVP, Sports Marketing & Mediasstilson@uspagl.com+001.561.227.6994Stacey KovalskyVice President, Global PR and Communicationsskovalsky@uspagl.com+001.561.790.8036SOURCE: U.S. Polo Assn.Related ImagesAgustina FondaLa Dolfina Tamera’s Adolfo Cambiaso hooks the mallet of his son Poroto Cambiaso of La Dofina Catamount in a defensive play to ultimately win the U.S. Open Polo Championship® in a score of 12-8.Agustina FondaThe record-breaking crowd at the USPA National Polo Center (NPC) watching the heart-pounding U.S. Open Polo Championship® Final. Copyright 2025 ACN Newswire via SeaPRwire.com.

Key Highlights:- Green jobs in Singapore show 27% year-on-year growth with 12% month-on-month increase in March '25- Engineering, Construction & Infrastructure sector leads sustainability hiring with 29% share of green jobs- Consulting & Strategy sector accounts for 11% of sustainability-focused positions- ESG Analyst emerges as the role with the highest growth in demand 28% year-on-year - Singapore's green job sector projected to grow by 11% in 2025SINGAPORE, Apr 23, 2025 - (ACN Newswire via SeaPRwire.com) - Jobs platform, foundit (formerly Monster APAC & ME), today published the foundit Earth Day Special Singapore Report as part of the foundit Insights Tracker (fit). The report highlights significant growth in sustainability-driven hiring across Singapore's employment landscape.The tracker reveals an overall year-on-year (YoY) growth of 27% in green jobs, with a positive month-on-month (MoM) increase of 12% in March 2025, building on the 17% growth seen in February."Singapore’s green job market is witnessing remarkable growth," said V Suresh, CEO of foundit. "Our Earth Day Special report reveals a 27% year-on-year surge in green job opportunities, underscoring the nation’s steadfast commitment to sustainability and environmental stewardship. Pivotal sectors such as Engineering, Construction, and Sustainable Finance are spearheading this transition, driving substantial and lasting impact. This upward trend not only mirrors the evolving demands of the labour market but also resonates strongly with the objectives of Singapore’s Green Plan 2030, reaffirming sustainability as a cornerstone of the country’s long-term economic vision.”Engineering, Construction and Consulting sectors lead sustainability hiringThe Engineering, Construction & Infrastructure sector has emerged as the frontrunner in sustainability-focused hiring, accounting for 29% of all green job opportunities across monitored industries. This dominance reflects Singapore's commitment to eco-friendly urban development and sustainable infrastructure projects. Representing 11% of green job postings, the Consulting & Strategy sector is gaining momentum, driven by growing demand for sustainability consultants and environmental strategists as organisations integrate ESG frameworks into their operations.Education and Manufacturing & Production sectors each contribute 7% of sustainability-focused positions, highlighting increased focus on workforce reskilling and the transition toward cleaner production practices.Energy and Research & Technology sectors each account for 6% of green job opportunities, supporting innovations in renewables, green hydrogen, and sustainable R&D initiatives across Singapore.ESG and Renewable Energy professionals lead demand among sustainability rolesIn terms of sustainability-focused roles, ESG Analysts witnessed the highest growth with a 28% year-on-year increase, underscoring the rising importance of environmental, social, and governance considerations in business operations.Sustainability Consultants followed closely with 24% year-on-year growth, while Renewable Energy Engineers showed strong demand with 22% year-on-year growth, reflecting Singapore's push toward clean energy alternatives.Other high-growth roles include Green Supply Chain Managers (+19%), Environmental Policy Officers (+16%), Carbon Credit Analysts (+14%), and Climate Risk Specialists (+13%), indicating broad demand across sustainability functions.The report highlights evolving skill requirements, with employers increasingly seeking cross-functional expertise that blends engineering, finance, policy, and digital proficiency to meet regulatory and ESG expectations.Looking ahead, the green job sector in Singapore is projected to grow by 11% in 2025, with renewable energy, electric mobility, and green infrastructure identified as key growth drivers.The foundit Insights Tracker is a comprehensive monthly analysis of online job posting activity conducted by jobs platform, foundit. Based on a real-time review of millions of employer job opportunities culled from a large, representative selection of online career outlets, the foundit Insights Tracker (FIT) presents a snapshot of employer online recruitment activity nationwide.About foundit - APAC & Middle Eastfoundit, formerly Monster (APAC & ME), is Asia’s leading jobs and talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. In addition to its innovative AI-powered job search, foundit offers e-learning, assessments, and services related to resume creation and interview preparation. foundit has connected over 120 million job seekers across 18 countries with the right job roles and upskilling opportunities. Over the last two decades, the company has been a leader in the world of recruitment solutions and has launched cutting-edge tools to give recruiters access to passive candidates in addition to active ones. With its advanced technology, foundit is efficiently bridging the talent gap across industry verticals, experience levels, and geographies.Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalised job searches and offer precision hiring.To learn more about, foundit in APAC & Gulf, visit: www.foundit.sg |www.foundit.com.ph | www.foundit.my | www.foundit.in | www.founditgulf.com | http://www.foundit.hk | www.foundit.id For media inquiries or further information, please contactNamrata SharmaNamrata.sharma@adfactorspr.comContact number - +65 81383034 Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – In recent years, with the launch of top-level design for nuclear medicines and the implementation of supporting policies, the domestic nuclear medicine industry has ushered in a golden period of development. According to the data analysis of BCC Research, there will be a growth in the global nuclear medicine market from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% during the forecast period from 2024 to 2029. Meanwhile, Medraysintell, a market intelligence agency specializing in radiotherapy and nuclear medicine, predicts that there will be a growth of about $30 billion in the global nuclear medicine market in 2030.As a leading nuclear medicine company in China, CIRC (01763.HK) recently disclosed its annual report for 2024 as of December 31st. In 2024, CIRC achieved a remarkable growth in revenue and net profit, which not only delivered a satisfactory answer on the performance level, but also showed a strong technical transformation capability in nuclear medicine research and development.Year-by-year growth facilitated nuclear medical equipment to become a new engineAccording to the financial data, CIRC achieved revenue of RMB 7.575 billion in 2024, with a year-on-year increase of 14.2%, and the net profit of RMB 880 million, with a year-on-year increase of 13.3%.From the perspective of branch business, all fields have blossomed in an all-round way. As the core pillar of the company, the nuclear medicine business achieved revenue of RMB 4.168 billion, accounting for 55% of the total revenue. Among them, the income of imaging diagnosis and therapeutic radiopharmaceuticals increased by 4.1% year-on-year, and the distribution of medical centers all over the country achieved remarkable results. The income of Technetium-labeled medicines increased by 8.7% year-on-year. The breath test business continued to maintain a stable high market share, achieving revenue of RMB 2.35 billion, by a year-on-year increase of 1.1%.It is worth noting that in 2024, CIRC accelerated the localization of high-end radiotherapy equipment, and nuclear medical equipment and related services became the new engine of growth, with revenue reaching RMB 1.223 billion, a year-on-year increase of 31.0%. The new generation of Precision radiation therapy planning system was successfully approved for medical device registration certificate, and the world’s first spiral tomotherapy system, Tomo C, was delivered to Shandong Cancer Hospital for installation, which was successfully selected intothe 2024 high-end medical equipment promotion and application project of two ministries and commissions (Ministry of Industry and Information Technology/National Health Commission) and Tianjin First (Set) Major Technical Equipment Promotion and Application Guidance Catalog (Version 2024), with sales during the year leading in the domestic market.CIRC recorded RMB 716.1 million in revenue from radioactive source products, representing a year-on-year increase of 22.2%. Gamma knife source and non-destructive testing radioactive source continued to maintain a stable and high market share. CNNC Qinshan Isotope successfully obtained the Class A radiation safety license, and the cobalt-60 radioactive source production line delivered 2 million curies.40-year solid accumulation in nuclear technology laid a solid foundationAs the main body of the nuclear technology application industry of CNNC, CIRC has been accumulated in the industry for over 40 years, forming a “6+N” industrial layout with six major businesses as the core, including nuclides, nuclear medicines, nuclear medical equipment, integrated solution for nuclear medicine, radioactive source and application, and irradiation application. During the Reporting Period, CIRC achieved 224 patent authorizations, with a total of 969 valid patents, and continued to maintain the leading position of the R&D investment intensity in the industry.In the field of nuclear medicine research and development, CIRC has demonstrated a strong technical capability from research results turned into technologies. Sodium fluorine-18 injection obtained the drug registration certificate from the National Medical Products Administration and was approved for marketing, filling the market gap of PET diagnostic imaging agent in the field of bone imaging in China. Iodine-131-MIBG injection is close to the end of Phase III clinical trial. After the drug is launched, it will provide a new diagnostic method for neuroendocrine tumors such as pheochromocytoma and neuroblastoma. It is worth noting that CIRC has proactively laid out integrated diagnosis and treatment drugs, and the research and development of Lutetium-177oxyoctreotide injection is progressing smoothly, marking a strategic upgrade from simple diagnosis to precise diagnosis and treatment.In addition to stabilizing the base of nuclear medicine, CIRC has gradually increased its emphasis on nuclear medical equipment. According to the sales data in recent years, the income of nuclear medical equipment has steadily increased. In 2024, a new generation of Gamma Knife was approved, which integrated CBCT image guidance, six-dimensional bed auto-correction, and other intelligent technologies, and the treatment efficiency was improved by 30%. In the Class A large-scale medical equipment market, CIRC occupies an absolute dominant position through its holding subsidiary, CNNC ACCURAY. In February this year, 19 of the 28 high-end radiotherapy equipment in the second round of Class A large-scale medical equipment licensing list released by the National Health Commission came from CNNC ACCURAY, accounting for 68% of the market. It is worth noting that the breakthroughs in the fields of Cobalt-60-based Stereotactic Therapy System also promote the localization of radiotherapy equipment.Facing the explosive growth of the nuclear medicine market, CIRC Accelerated Pharmaceutical Center continues to expand its nationwide network layout. In 2024, a new positron emission drug production line has been added in Lanzhou, with a total of 23 lines put into operation; Newly added Fuzhou Technetium Drug Production Line, with a total of 27 units put into operation. CIRC has built the first 10,000 Curie level lutetium-177 production line and a thousand level germanium-gallium [68Ge-68Ga] generator production line in the country, achieving a breakthrough in the localization of high-end nuclides.It is worth noting that CIRC has created a hierarchical innovation ecosystem through the "Parent-Subsidiary Collaboration" model. In 2024, its subsidiaries, CNNC HEADWAY (breath test) and CNNC Chengdu Gaotong (nuclide), were awarded the national level specialized, refined, and new "little giants" enterprise, bringing the total number of specialized, refined, and new enterprises under CIRC to 18. Among them, CNNC HEADWAY dominates the breath testing market with its integrated solution of "medicine box+instrument", while CNNC Chengdu Gaotong has become a benchmark in the field of nuclear technology application through its full chain layout of "Nuclide-Drug-Equipment". This innovative system, resembling an "Aircraft carrier battle group", provides sustainable momentum for the company's long-term growth.Expanding Development Space with Globalization LayoutAs the main force of CNNC Group's march towards people's life and health science and technology and the main channel for the transformation of advanced nuclear science and technology achievements, CIRC responds to the Group's "Overall&Coordination" internationalization strategy and the national "the Belt and Road" initiative, vigorously promotes the internationalization strategy and constantly expands overseas markets. By 2024, the export revenue will reach RMB 627 million, and the products will be exported to dozens of countries and regions such as Brazil, Peru, and Nigeria.At the beginning of this year, we successfully signed a contract for the supply of equipment for a million curies design source gamma irradiation station in Bangladesh. This is another equipment supply project for irradiation stations that has landed after winning the bid for the Bangladesh Institute of Nuclear Agriculture's design source gamma irradiation station project in 2024. After its completion and operation, the irradiation station will mainly serve the irradiation sterilization of medical products in Bangladesh, significantly improving the quality level and production processing capacity of local medical products, assisting the development of Bangladesh's medical industry, and benefiting local people's livelihoods.In Nigeria, CIRC successfully signed a contract for the overall supply of nuclear medical equipment, achieving the first successful landing of the Group's nuclear medical equipment overall supply project. In addition, CIRC actively expands into the ASEAN market and successfully exports cold chain drugs to Thailand; We have also signed strategic cooperation agreements with multiple entities in Brazil to support the signing of a memorandum of understanding on strategic cooperation in the field of nuclear technology applications between the National Atomic Energy Agency and Brazil.ConclusionAgainst the backdrop of policy support and sustained market demand, CIRC stated to focus on the "Do as the Demard of the Country" and further deepen the coordinated development of nuclear medicine and high-end equipment around the "Healthy China" strategic framework. According to its 2025 plan, key projects such as Qinshan Isotope Base, Phase I of Jiajiang Radioactive Source Base, and Phase I of North China Pharmaceutical Base will be promoted according to milestones, involving nuclide production, radioactive source manufacturing, and pharmaceutical supply chain layout. At the same time, CIRC will enhance its digital diagnosis and treatment service capabilities through the iteration of smart nuclear medicine projects, and plans to launch no less than 3 intelligent systems within this year.At the international level, CIRC will continue the market expansion strategy along the "the Belt and Road", rely on the existing business models such as radiation station equipment export, nuclear medical equipment overall solution output, focus on the cooperation in South America, Southeast Asia, the Middle East, North Africa and other regional markets, and further improve the global market penetration rate in the future or through localized cooperation.The management of the Company stated that in 2025, CIRC will continue to strengthen technological innovation, improve the modern industrial system, accelerate the cultivation and development of new quality productivity, continuously enhance core functions, improve core competitiveness, and accelerate the establishment of an internationally-renowned supply group of technology, product and service in isotope and radiation. Copyright 2025 ACN Newswire via SeaPRwire.com.

佛羅里達州西棕櫚灘，2025年4月22日 - (亞太商訊 via SeaPRwire.com) - 2025年U.S. Open馬球錦標賽®於3月26日至4月20日在佛羅里達州棕櫚灘縣的美國馬球協會國家馬球中心（USPA National Polo Center, NPC）舉行，為觀眾呈現頂級馬球賽事。本週日，La Dolfina Tamera隊在總決賽中以12比8擊敗La Dolfina Catamount隊，贏得勝利，現場觀眾人數創下新高。Agustina FondaLa Dolfina Tamera隊贏得U.S. Open馬球錦標賽®獎盃。鎖定ESPN，觀看U.S. Open馬球錦標賽本次總決賽由ESPN傳奇播報員克里斯·福勒主持，在美國馬球協會主場球場上演，現場氣氛熱烈。這場精彩對決將通過多個ESPN平台向全球觀眾播出，包括美國東部時間4月26日（週六）上午10:30在ESPN2頻道，以及4月27日（週日）黃金時段在ESPNews頻道播出。請查詢您所在地的播出時間。U.S. Polo Assn. 持續支持馬球運動與馬類慈善事業作為北美最具聲望的馬球錦標賽事，U.S. Open 馬球錦標賽匯聚了全球最優秀的馬球選手和頂級馬匹。今年賽事再度由美國馬球協會（USPA）官方品牌 U.S. Polo Assn. 提供支持，包括為參賽隊伍提供印有品牌標誌的球衣、為國家馬球中心（NPC）工作人員與裁判提供制服、為選手頒發獎品，並向多家本地慈善機構捐贈資金。整個賽季中，這一全球性的運動生活方式品牌已向馬球慈善與馬類福利等項目捐贈約25,000美元。受益機構包括：Homes for Horses Coalition、馬球博物館與名人堂、Polo for Life、馬球選手支持基金會、Polo Pony Rescue、Polo Training Foundation、Replay Polo、退役賽馬計劃、Vinceremos 治療騎乘中心、以及 Work to Ride 計劃。「U.S. Polo Assn. 很榮幸再次支持 U.S. Open 馬球錦標賽，這項賽事將通過 ESPN 各大平台播出，成為春季最重要的體育盛事之一，與高爾夫大師賽和肯塔基賽馬會齊名。」USPA Global 總裁兼首席執行官 J. Michael Prince 表示。該公司負責經營並推廣 U.S. Polo Assn. 品牌。「我們非常榮幸今年由 ESPN 傳奇主播克里斯·福勒主持賽事，並由 Kenny Rice 和 Adam Snow 聯袂講解。隨著我們不斷吸引全球更多體育迷和消費者，也讓更多人接觸和了解馬球這項精彩運動。」現場觀眾人數創紀錄，巔峰對決震撼上演「祝賀 La Dolfina Tamera 隊在 U.S. Open 馬球錦標賽中取得非凡勝利，」美國馬球協會（USPA）主席斯圖爾特·阿姆斯特朗（Stewart Armstrong）表示，「我還要感謝並致敬所有在 2025 賽季參與比賽的隊伍，你們為這項運動全力以赴。」阿姆斯特朗補充說：「感謝所有的支持者、選手、贊助商以及熱愛馬球運動的球迷們，是你們的熱情與支持成就了這個精彩的賽季。」巔峰對決，現場觀眾人數創歷史新高在國家馬球中心（NPC），數千名觀眾現場觀賞了「馬球三冠王系列賽」（Gauntlet of Polo®）的最終戰。這項系列賽事包括 C.V. Whitney 杯®、USPA 金盃®和 U.S. Open 馬球錦標賽。今年的賽事每一周都吸引大量觀眾，總決賽更是高潮迭起，精彩紛呈，兩支勁旅由世界頂尖馬球選手領銜——La Dolfina Tamera 隊包括 10桿選手阿道夫·坎比亞索（Adolfo Cambiaso）、迭戈·卡瓦納（Diego Cavanagh）、馬特·科波拉（Matt Coppola）和亞歷山德拉·波科波拉（MattAlmooba）（Almodua）和亞梅隆·波科波拉（Matt Coppina）和亞梅隆·波科波拉（Almoka；球隊則由 10桿選手波羅托·坎比亞索（Poroto Cambiaso）、傑西·布雷（Jesse Bray）、魯菲諾·梅洛斯（Rufino Merlos）和斯科特·德文（Scott Devon）組成。這是連續第二年，U.S. Open 馬球錦標賽總決賽呈現由世界頂級馬球父子選手之間的世紀對決。現年50歲的阿道夫·坎比亞索在過去兩屆 U.S. Open 總決賽中連續敗北，上一次正是敗給了自己19歲的兒子波羅托。今年他捲土重來，在這場比賽中成功復仇，拿下個人第10座 U.S. Open 冠軍獎盃。更有意義的是，就在本週，阿道夫剛剛迎來50歲生日，這座獎盃無疑是他送給自己的完美生日禮物。阿道夫被譽為馬球史上最偉大的選手，不僅在阿根廷公開賽中被擊敗超過17座冠軍獎杯，更被公認為「史上最偉大」（GOAT）之一，與老虎伍茲、邁克爾喬丹和湯姆布雷迪等體壇傳奇齊名。50歲的阿道夫·坎比亞索擊敗19歲的兒子波羅托，重奪冠軍獎盃現年50歲的阿道夫·坎比亞索在過去兩屆 U.S. Open 總決賽中連續敗北，上一次正是敗給了自己19歲的兒子波羅托。今年他捲土重來，在這場比賽中成功復仇，拿下個人第10座 U.S. Open 冠軍獎盃。更具意義的是，就在本週，阿道夫剛迎來50歲生日，這座獎盃無疑是他送給自己最完美的生日禮物。阿道夫被譽為馬球歷史上最偉大的選手，不僅在阿根廷公開賽中斬獲超過17座冠軍，更被公認為「史上最偉大」（GOAT）之一，與老虎伍茲、麥可·喬丹和湯姆·布雷迪等體壇傳奇齊名。La Dolfina Catamount 隊在第一節比賽（Chukker 1）一開始占據優勢，但 La Dolfina Tamera 很快扭轉局勢，比分始終緊咬。第三節結束時，雙方戰成6比6平。波馬（Poma）在第3、4與第5節中連續貢獻關鍵進球，加上阿道夫一記精彩的遠射，Tamera 隊逐步掌控局勢並持續領先。儘管波羅托全場攻入5球，布雷（Bray）也在第6節（即最後一節）為 Catamount 隊進球，將比分追至11比8，但時間所剩無多，難以逆轉局勢。最終，科波拉（Coppola）打入制勝一球，將比分定格在12比8，Tamera 隊鎖定勝局。La Dolfina Tamera 隊的波馬憑藉全場最高的4個進球榮獲MVP，阿道夫則貢獻了3個進球。美國馬球協會國家馬球中心：世界冬季馬術之都NPC（國家馬球中心）作為全球頂級馬球場地，位於佛羅里達州棕櫚灘縣，觀眾可從多種尊貴角度觀賽，包括場邊看台、包廂、尾箱帳篷、主看台，以及 U.S. Polo Assn. MVP 休息區——這裡同時也是標誌性的「週日馬球早午餐」舉辦地。此外，體育迷還能在 NPC 現場專屬的 USPA 旗艦店盡情選購限量版運動奢品，包括 The Polo Club 系列與 U.S. Polo Assn. 全球系列，為自己帶回一份馬球文化的紀念。今年新增的亮點之一是與環保品牌 4ocean 聯名的定製手鏈，作為兩大品牌長期合作的一部分。4ocean 也是 2025 年 U.S. Open 馬球錦標賽的官方回收合作夥伴。圖片來源：Agustina Fonda1. La Dolfina Tamera 隊贏得 U.S. Open 馬球錦標賽® 冠軍獎盃。2. La Dolfina Tamera 隊的阿道夫·坎比亞索（Adolfo Cambiaso）在一次關鍵防守中成功勾住了其子、La Dolfina Catamount 隊球員波羅托·坎比亞索（Poroto Cambiaso）的球桿，最終幫助球隊以 12 比 8 贏得 U.S. Open 馬球錦標賽®。3. 在 USPA 國家馬球中心（NPC），創紀錄的觀眾人數現場觀看了這場驚心動魄的 U.S. Open 馬球錦標賽® 總決賽。數千名觀眾齊聚國家馬球中心，共同見證「馬球三冠王系列賽」（Gauntlet of Polo®）最終戰的精彩對決。該系列賽包含 C.V. Whitney 杯®、USPA 金杯®以及 U.S. Open 馬球錦標賽。今年每一週的賽事均吸引破紀錄人潮，而總決賽更是高潮迭起、精彩紛呈。兩支參賽隊伍由世界頂尖馬球選手組成——La Dolfina Tamera 隊陣容包括 10杆選手阿道夫·坎比亞索（Adolfo Cambiaso）、迭戈·卡瓦納（Diego Cavanagh）、馬特·科波拉（Matt Coppola）以及亞歷杭德羅·波馬（Alejandro Poma）；La Dolfina Catamount 隊則由 10杆選手波羅托·坎比亞索（Poroto Cambiaso）、傑西·布雷（Jesse Bray）、魯菲諾·梅洛斯（Rufino Merlos）和斯科特·德文（Scott Devon）組成。這是連續第二年由這對父子——Adolfo 與 Poroto Cambiaso——在 U.S. Open 馬球錦標賽總決賽中正面交鋒，奉上了一場馬球史上的經典對決。關於 U.S. Polo Assn. 和 USPA GlobalU.S. Polo Assn. 是美國馬球協會（USPA）的官方品牌，該協會創立於1890年，是北美最大的馬球俱樂部與馬球運動員聯盟。U.S. Polo Assn. 擁有數十億美元的全球品牌價值，並通過超過 1,100 間品牌零售店及數千個銷售據點，在全球超過 190 個國家提供男裝、女裝、童裝、配件與鞋類產品。透過與美國 ESPN 及印度 Star Sports 的歷史性協議，U.S. Polo Assn. 贊助的多項世界頂級馬球賽事現已首次轉播至全球數以百萬計的體育迷，讓這項激動人心的運動走向世界舞台。根據《License Global》報導，U.S. Polo Assn. 長期被評為全球頂尖體育授權品牌之一，與 NFL、NBA 和 MLB 並列。此外，該品牌也因其在全球與數位市場的成長，獲得眾多國際獎項肯定。U.S. Polo Assn. 曾登上《富比士》、《財富》、《現代零售》和《GQ》等主流媒體版面，也多次出現在 Yahoo Finance 和 Bloomberg 等財經平台。欲了解更多資訊，請造訪 uspoloassnglobal.com 並追蹤 @uspoloassn。USPA Global 是 USPA 的子公司，負責經營全球價值數十億美元的 U.S. Polo Assn. 品牌。透過其子公司 Global Polo Entertainment（GPE），USPA Global 同時營運提供體育與生活風格內容的 Global Polo TV。欲了解更多賽事內容，請造訪 globalpolo.com。聯絡資訊Shannon Stilson體育行銷與媒體副總裁sstilson@uspagl.com+001.561.227.6994Stacey Kovalsky全球公關與傳播副總裁skovalsky@uspagl.com+001.561.790.8036Agustina Fonda 攝影La Dolfina Tamera 隊的阿道夫·坎比亞索（Adolfo Cambiaso）在一次防守中勾住了其子、La Dolfina Catamount 隊的波羅托·坎比亞索（Poroto Cambiaso）的球桿，最終帶領球隊以 12 比 8 贏得 U.S. Open 馬球錦標賽® 冠軍。Agustina Fonda 攝影創紀錄的人潮齊聚 USPA 國家馬球中心（NPC），現場觀賞這場扣人心弦的 U.S. Open 馬球錦標賽® 總決賽。來源：U.S. Polo Assn. Copyright 2025 亞太商訊 via SeaPRwire.com.